BioCentury
ARTICLE | Company News

University of Queensland, Ultragenyx deal

September 8, 2014 7:00 AM UTC

The UniQuest Pty. Ltd. commercialization arm of the University of Queensland granted Ultragenyx exclusive, worldwide rights to IP related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with Ultragenyx's triheptanoin ( UX007). The company declined to disclose financial terms. Triheptanoin is in Phase II trials to treat long-chain fatty acid oxidation disorders and to treat glucose transporter type-1 deficiency syndrome in patients who have failed a ketogenic diet and continue to have breakthrough seizures. Interim data from both trials are expected next year. The product is a synthetic compound that provides medium-length, odd-chain fatty acids that are metabolized to replace intermediate substrates in fatty acid oxidation and in the tricarboxylic acid (TCA) cycle. ...